Doximity Q3 Earnings: Outpacing Even Management's Expectations
I previously rated Doximity, Inc. a buy due to strong Q2 earnings, favorable DCF analysis, and its strategic position in the healthcare industry. Q3 earnings showed continued strength, with DOCS stock up 56% compared to the S&P 500's 2% return since my last analysis. Updated DCF valuation, incorporating management guidance and industry trends, suggests a new price target of $90, indicating 14% upside from today.
Digital Health Platform Doximity Stock Jumps On Upbeat Annual Outlook, Analysts Raise Forecast
Doximity Inc DOCS stock is trading higher on Friday after the company reported third-quarter fiscal 2025 results that beat analysts' expectations and upbeat guidance.
Why Doximity Stock Skyrocketed Higher Today
According to data provided by S&P Global Market Intelligence, the "Bloomberg platform for medical professionals," Doximity (DOCS 33.69%), saw its shares spike 34% as of 11:20 a.m. ET Friday.
Doximity shares pop 30% on revenue beat, rosy guidance
Doximity shares ripped higher Friday, a day after reporting fiscal third-quarter results that beat expectations for revenue and guidance. Analysts called it a "statement type of quarter" for the company.
Doximity, Inc. (DOCS) Q3 2025 Earnings Call Transcript
Doximity, Inc. (DOCS) Q3 2025 Earnings Call Transcript
Doximity (DOCS) Q3 Earnings and Revenues Top Estimates
Doximity (DOCS) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.29 per share a year ago.
Doximity shares soar 21% after company beats on revenue, raises fiscal year guidance
Doximity reported third-quarter fiscal 2025 results that beat analysts' expectations for revenue and guidance. The company's revenue increased 25% to $168.6 million in its third quarter.
Doximity Surpasses EPS, Revenue Goals
Doximity (DOCS 0.21%), a digital platform for U.S. medical professionals, released its fiscal third-quarter earnings on Feb. 6, 2025. The company reported impressive results, surpassing both analyst forecasts and its own guidance.
Dr Martens recovery plan to be tested in forthcoming update
Dr Martens PLC (LSE:DOCS) shares have been rising recently, a rare event since the iconic boot maker listed in 2021. New chief executive Ije Nwokorie, ex-Wolff Olins and Apple, came with a lot of goodwill and that has helped but next week's update will be a more serious test.
The Zacks Analyst Blog Doximity, Omnicell, Embecta, Cencora and EDOC
Doximity, Omnicell, Embecta, Cencora and EDOC are included in this Analyst Blog.
Doximity: Upgraded To Buy Amid Promising Growth And Strong Execution
Upgraded Doximity to a buy rating due to recent share price pullback, stronger engagement metrics, and deeper client relationships, creating a compelling entry point. DOCS reported 20% y/y revenue growth in 2Q25, surpassing management's guidance, with increased user adoption and higher revenue per user driving performance. The adoption of AI-driven tools and expanded Client Portal access are enhancing the Company's value proposition, leading to higher engagement and better-targeted advertising for pharma clients.
Doximity (DOCS) Ascends But Remains Behind Market: Some Facts to Note
Doximity (DOCS) closed the most recent trading day at $58.18, moving +0.61% from the previous trading session.
